Summary & Overview
HCPCS C9818: Suzetrigine, Oral, 1 mg
HCPCS Level II code C9818 designates Suzetrigine, oral, 1 mg. As a product-specific HCPCS Level II code, it identifies a discrete pharmaceutical item for billing and inventory in outpatient settings. Nationally, product-level HCPCS codes like C9818 matter for accurate pharmacy claims, drug utilization tracking, and payer coverage determinations for specialty or newly marketed agents.
Key payers discussed include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. Coverage and reimbursement practices for HCPCS product codes vary across commercial and public payers; product codes are used in claims to report the drug supplied and support medical and pharmacy benefit adjudication.
Readers will find contextual information on the clinical identity of the code (an oral 1 mg formulation of suzetrigine), expected service setting (outpatient pharmacy or clinician-directed outpatient medication management), and the role of HCPCS Level II product codes in billing workflows. The publication also provides benchmarks and policy-focused insights relevant to payers and provider billing operations, and outlines typical documentation and claim elements where available.
Data not available in the input: specific modifiers, associated taxonomies, ICD-10 diagnoses, related codes, and detailed payer-specific coverage policies.
Billing Code Overview
HCPCS Level II code C9818 represents Suzetrigine, oral, 1 mg. This code denotes the medication product and strength for an oral pharmaceutical formulation of suzetrigine.
-
Service type: Medication administration/product (oral pharmaceutical)
-
Typical site of service: Outpatient pharmacy dispensing or clinician-directed outpatient medication management
Data not available in the input for modifiers, associated taxonomies, ICD-10 diagnoses, related codes, and service line.
Clinical & Coding Specifications
Clinical Context
A typical patient is an adult with a focal seizure disorder or neuropathic pain being managed in an outpatient neurology clinic or specialty pharmacy program. The patient has a new prescription for C9818 (Suzetrigine, oral, 1 mg) after prior trials of standard antiepileptic or neuropathic agents produced inadequate control or intolerable adverse effects. The clinical workflow includes a neurology or pain specialist evaluation, review of prior therapies and diagnostic testing, medication reconciliation, patient counseling on dosing and adverse effects, and coordination with specialty pharmacy for prior authorization and medication dispensing. Initial visits document baseline seizure frequency or pain scores, concurrent medications, renal and hepatic function, and risk factors for drug interactions. Follow-up visits occur at scheduled intervals to assess efficacy, dose adjustments, adverse events, and adherence. Typical sites of service are outpatient neurology or pain clinics, specialty pharmacy dispensing centers, and potentially ambulatory infusion or observation units when monitoring for initial tolerability is required.
Coding Specifications
| Modifier | Description | When to Use |
|---|---|---|
25 | Significant, separately identifiable evaluation and management service on the same day as a procedure | Use when a clinician performs a substantial E/M visit on the same day is administered or dispensed and documentation supports a distinct service |